No Data
No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Racing ahead in the field of synthetic biology, analyzing the innovation and opportunities of Sihuan Pharm (0460.HK) in the medical beauty market.
Recently, Danone's investment of over 16 million euros in the synthetic biology field has attracted the attention of many investors. This field is rapidly becoming a hot topic of the current market. In particular, polyhydroxyalkanoates (PHAs) have begun to emerge due to their unique biodegradability and biocompatibility, demonstrating their enormous potential for application in multiple industries. In the medical beauty industry, this trend is particularly evident. With the increasing pursuit of health and beauty among consumers, the application of PHA has brought revolutionary innovation to medical beauty products. It can not only provide safer and more effective beauty solutions, but also bring new opportunities to the industry.
Sihuan Pharma Unit's Microvascular Disease Drug Gets China Registration Approval
Sihuan Pharmaceutical (HKG:0460) has received drug registration approval from China's National Medical Products Administration for the calcium dobesilate capsules developed by its subsidiary Huisheng
Sihuan Pharm (00460.HK): Hydroxyphenol sulfonate calcium capsules developed by Huisheng Biotech have been approved for listing by the National Medical Products Administration.
On June 27th, Gelonghui announced that Huisheng Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of the Sihuan Pharmaceutical Group (00460.HK), has obtained a drug registration certificate issued by the China National Medical Products Administration for the development of calcium dobesilate capsules. This is considered to be consistent in quality and efficacy with generic drugs. Calcium dobesilate is a capillary protector used to improve microcirculation in the microvessels, regulating the physiological function of blood vessel walls, increasing permeability, reducing resistance, reducing plasma viscosity, reducing platelet aggregation and thus preventing thrombosis and improving the flexibility of red blood cells. Calcium dobesilate
No Data
102326032 : Pro
投智者KTOP 102326032: It's not... Cham..
102326032 : Too chim, don’t understand haha
102326032 : So you own this stocks?
投智者KTOP 102326032: Ya.. I expect it up.
View more comments...